Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 23, 2021 11:00 ET | Source: Entera Bio Ltd.

Entera Bio to Conduct Annual Shareholders Meeting on October 4, 2021

BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will host its...
August 23, 2021 08:30 ET | Source: Entera Bio Ltd.

Entera Bio to Present at H.C. Wainwright 23rd Annual Global Investment Conference

BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Company’s CEO...
August 16, 2021 06:30 ET | Source: Entera Bio Ltd.

Entera Bio Reports Second Quarter 2021 Financial Results and Provides Clinical Updates

‒ Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 6-month Bone Mineral Density Endpoint; Primary and Key Secondary Endpoints Met ‒ ‒ Preparing for End of Phase 2 Meeting with FDA for...
August 13, 2021 16:30 ET | Source: Entera Bio Ltd.

Entera Bio to Report Business and Financial Results for the Quarter ended June 30, 2021, on August 16, 2021

BOSTON and JERUSALEM, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business...
August 02, 2021 08:30 ET | Source: Entera Bio Ltd.

Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting

‒ The Study’s Primary Endpoint was Met; P1NP, a Biochemical Marker of Bone Formation, was Significantly Increased at Month 3 in EB613 2.5 mg Treatment Group Versus Placebo ‒ ‒ Full 3-Month...
June 28, 2021 15:15 ET | Source: Entera Bio Ltd.

Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis

BOSTON and JERUSALEM, June 28, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will conduct a...
June 23, 2021 08:30 ET | Source: Entera Bio Ltd.

Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the Study Met Its Primary and Key Secondary Endpoints

Subjects receiving the 2.5 mg dose of EB613 showed significant dose-related increases in BMD at the lumbar spine, total hip, and femoral neck at 6 monthsSubjects receiving the 2.5 mg dose of EB613 for...
June 17, 2021 08:00 ET | Source: Entera Bio Ltd.

Entera Bio Receives Foundational Patent for its Oral PTH using its Platform Oral Protein Delivery Technology in European Union

‒ Oral delivery technology has potential to transform $20 billion injectable biologics market ‒ ‒ Final BMD results from company’s Phase 2 Osteoporosis study of EB 613 expected in Q2/2021 ‒ ...
May 20, 2021 08:00 ET | Source: Entera Bio Ltd.

Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates

‒ Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 3-Month Primary Endpoint; Final Data Including BMD Expected Q2:21 ‒ ‒ Entera’s Oral Delivery Platform Shows Potential in Indications Including...
April 20, 2021 08:45 ET | Source: Entera Bio Ltd.

Entera Announces Ron Mayron, a Global Pharma Leader, Joins its Board of Directors

BOSTON and JERUSALEM, April 20, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that Ron Mayron...